The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 5
  • 1
    Harimohan, Bhavani, Dr
    Research And Development Director born in December 1979
    Individual (1 offspring)
    Officer
    2024-08-26 ~ now
    OF - Director → CIF 0
  • 2
    Faltum, Carsten Kronsbjerg
    Pharmaceutical Consultant born in February 1969
    Individual (3 offsprings)
    Officer
    2019-07-21 ~ now
    OF - Director → CIF 0
  • 3
    Cohen, Laurence John
    Solicitor born in September 1951
    Individual (16 offsprings)
    Officer
    2017-11-28 ~ now
    OF - Director → CIF 0
  • 4
    Bakri, Rached Sami, Dr
    Entrepreneur born in July 1977
    Individual (3 offsprings)
    Officer
    2024-05-20 ~ now
    OF - Director → CIF 0
  • 5
    Professor Mustafa Bilgin Ali Djamgoz
    Born in August 1952
    Individual (7 offsprings)
    Person with significant control
    2017-11-28 ~ now
    PE - Ownership of shares – More than 50% but less than 75% → CIF 0
    PE - Ownership of voting rights - More than 50% but less than 75% → CIF 0
    PE - Right to appoint or remove directors → CIF 0
Ceased 5
  • 1
    Millard, Brian Percival De Thorpe
    Consultant born in April 1943
    Individual (10 offsprings)
    Officer
    2019-09-25 ~ 2020-06-08
    OF - Director → CIF 0
  • 2
    Xeniadis, Vasileios, Dr.
    Banker born in July 1965
    Individual (1 offspring)
    Officer
    2019-09-25 ~ 2020-06-08
    OF - Director → CIF 0
    Dr Vasileios Xeniades
    Born in September 1965
    Individual (1 offspring)
    Person with significant control
    2019-09-25 ~ 2020-06-08
    PE - Has significant influence or control → CIF 0
  • 3
    Mr Laurence John Cohen
    Born in September 1951
    Individual (16 offsprings)
    Person with significant control
    2017-11-28 ~ 2019-09-25
    PE - Ownership of shares – More than 25% but not more than 50% → CIF 0
    PE - Ownership of voting rights - More than 25% but not more than 50% → CIF 0
  • 4
    Rahman, Ajmal
    Financial Consultant born in July 1963
    Individual (11 offsprings)
    Officer
    2020-07-01 ~ 2021-11-08
    OF - Director → CIF 0
  • 5
    Djamgoz, Mustafa Bilgin Ali, Prof
    University Professor born in August 1952
    Individual (7 offsprings)
    Officer
    2017-11-28 ~ 2024-03-24
    OF - Director → CIF 0
parent relation
Company in focus

CELEX ONCOLOGY INNOVATIONS LIMITED

Standard Industrial Classification
21100 - Manufacture Of Basic Pharmaceutical Products
Brief company account
Average Number of Employees
32023-01-01 ~ 2023-12-31
32022-01-01 ~ 2022-12-31
Intangible Assets
700,251 GBP2023-12-31
605,507 GBP2022-12-31
Fixed Assets
700,251 GBP2023-12-31
605,507 GBP2022-12-31
Debtors
Current
28,343 GBP2023-12-31
3,454 GBP2022-12-31
Cash at bank and in hand
128,201 GBP2023-12-31
411,609 GBP2022-12-31
Current Assets
156,544 GBP2023-12-31
415,063 GBP2022-12-31
Creditors
Current, Amounts falling due within one year
-67,827 GBP2023-12-31
-188,888 GBP2022-12-31
Net Current Assets/Liabilities
88,717 GBP2023-12-31
226,175 GBP2022-12-31
Total Assets Less Current Liabilities
788,968 GBP2023-12-31
831,682 GBP2022-12-31
Net Assets/Liabilities
788,968 GBP2023-12-31
831,682 GBP2022-12-31
Equity
Called up share capital
424 GBP2023-12-31
424 GBP2022-12-31
Share premium
874,513 GBP2023-12-31
874,513 GBP2022-12-31
Retained earnings (accumulated losses)
-85,969 GBP2023-12-31
-43,255 GBP2022-12-31
Equity
788,968 GBP2023-12-31
831,682 GBP2022-12-31
Intangible Assets - Gross Cost
Patents/Trademarks/Licences/Concessions
700,251 GBP2023-12-31
605,507 GBP2022-12-31
Intangible Assets
Patents/Trademarks/Licences/Concessions
700,251 GBP2023-12-31
605,507 GBP2022-12-31
Other Debtors
Current
3,827 GBP2023-12-31
3,454 GBP2022-12-31
Prepayments/Accrued Income
Current
24,516 GBP2023-12-31
Cash and Cash Equivalents
128,201 GBP2023-12-31
411,609 GBP2022-12-31
Trade Creditors/Trade Payables
Current
9,688 GBP2023-12-31
10,856 GBP2022-12-31
Other Creditors
Current
54,864 GBP2023-12-31
54,862 GBP2022-12-31
Accrued Liabilities/Deferred Income
Current
3,275 GBP2023-12-31
1,800 GBP2022-12-31
Creditors
Current
67,827 GBP2023-12-31
188,888 GBP2022-12-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
4,241,457 shares2023-12-31
4,241,457 shares2022-12-31
Par Value of Share
Class 1 ordinary share
0.00012023-01-01 ~ 2023-12-31
  • CELEX ONCOLOGY INNOVATIONS LIMITED
    Info
    Registered number 11085607
    101 New Cavendish Street, 1st Floor South, London W1W 6XH
    Private Limited Company incorporated on 2017-11-28 (7 years 7 months). The company status is Active.
    The last date of confirmation statement was made at 2024-04-05
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

qrcode

Privacy notice

© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.